)
Edge1 May 2026
Making the Marlboro Man
The story of Marlboro's transformation from a women's cigarette to a global icon: one of the most effective brand repositionings in history.
Karyopharm Therapeutics
Karyopharm Therapeutics (KPTI) investor relations material
Karyopharm Therapeutics Registration filing summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Registration filing summary4 May, 2026
Company overview and business model
Commercial-stage pharmaceutical company focused on novel cancer therapies targeting nuclear export mechanisms.
Lead product, XPOVIO (selinexor), is the first oral XPO1 inhibitor approved by the FDA in July 2019.
Pipeline includes small molecule XPO1 inhibitors for diseases with high unmet medical need.
Financial performance and metrics
As of April 29, 2026, 22,551,250 shares of common stock were outstanding; no preferred stock outstanding.
Historical net tangible book deficit as of December 31, 2025, was $(1,759.5) million, or $(96.09) per share.
After a $100M offering at $8.40/share, pro forma net tangible book deficit would be $(1,663.0) million, or $(55.04) per share.
Use of proceeds and capital allocation
Net proceeds intended for general corporate purposes, including working capital, R&D, clinical trials, debt repayment, hiring, administrative expenses, collaborations, and potential acquisitions or in-licensing.
Management retains broad discretion over allocation of proceeds.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Karyopharm Therapeutics
- 8.8 million shares registered for resale after $30M private placement; no proceeds to issuer.KPTI
Registration filing4 May 2026 - Selinexor plus ruxolitinib nearly doubled spleen response and improved survival in myelofibrosis.KPTIStudy result29 Apr 2026
- Board recommends approval of all proposals, including equity plan amendments and auditor ratification.KPTIProxy filing13 Apr 2026
- Shareholders approved increasing authorized shares and adjournment flexibility at the special meeting.KPTIEGM 202613 Apr 2026
- 2025 revenue reached $146.1M; net loss widened to $196.0M; pivotal trial data due in 2026.KPTIQ4 202512 Feb 2026
- Q2 2024 net income reached $23.8M on $42.8M revenue, aided by a $44.7M debt gain.KPTIQ2 20242 Feb 2026
- Selinexor shows robust efficacy in p53 wild-type endometrial cancer, with pivotal data due in 2025.KPTIJefferies 2024 Global Healthcare Conference1 Feb 2026
- Transformative phase III data in myelofibrosis, endometrial cancer, and myeloma expected by 2026.KPTIH.C. Wainwright 26th Annual Global Investment Conference 202421 Jan 2026
- SENTRY Phase 3 adopts Absolute TSS as co-primary endpoint, with strong early efficacy data.KPTIStudy Update17 Jan 2026
Next Karyopharm Therapeutics earnings date
Q1 202614 May, 2026
Karyopharm Therapeutics
Next Karyopharm Therapeutics earnings date
Q1 202614 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage